Based on the results of our present study, in the case of pulmonary ACC and MEC, oncotherapies against CLDN-2, -7, and -18 arise mostly, but in some cases CLDN-3 and -4 overexpression might also serve as a target. This evidence concerns the gene CLDN3 and mucoepidermoid carcinoma.